Patents by Inventor Eric L. Stangeland

Eric L. Stangeland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
    Patent number: 11723900
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: August 15, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS
    Publication number: 20220087995
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: February 3, 2021
    Publication date: March 24, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
    Patent number: 10946007
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: March 16, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS
    Publication number: 20200316048
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 8, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
    Patent number: 10722504
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: July 28, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS
    Publication number: 20200000792
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: September 4, 2019
    Publication date: January 2, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
    Patent number: 10441579
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: October 15, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS
    Publication number: 20190134019
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: January 3, 2019
    Publication date: May 9, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
    Patent number: 10206913
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 19, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity
    Patent number: 10138220
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising from about 0.05 ?g/mL to about 10 mg/mL of a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: November 27, 2018
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric L. Stangeland, Richard D. Wilson, Rose Yen
  • 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS
    Publication number: 20180289687
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 11, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
    Patent number: 10034870
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: July 31, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity
    Patent number: 9975875
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 22, 2018
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric L. Stangeland, Richard D. Wilson, Rose Yen
  • 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS
    Publication number: 20180050024
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: May 10, 2017
    Publication date: February 22, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland, Sheila Zipfel, Daniel D. Long
  • Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity
    Publication number: 20170362200
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Application
    Filed: August 18, 2017
    Publication date: December 21, 2017
    Inventors: Adam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric L. STANGELAND, Richard D. WILSON, Rose YEN
  • Diamide compounds having muscarinic receptor antagonist and ?adrenergic receptor agonist activity
    Patent number: 9771350
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: September 26, 2017
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric L. Stangeland, Richard D. Wilson, Rose Yen
  • Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity
    Publication number: 20170226082
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Application
    Filed: April 26, 2017
    Publication date: August 10, 2017
    Inventors: Adam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric L. STANGELAND, Richard D. WILSON, Rose YEN
  • Diamide compounds having muscarinic receptor antagonist and ? adrenergic receptor agonist activity
    Patent number: 9682957
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 20, 2017
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric L. Stangeland, Richard D. Wilson, Rose Yen
  • 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
    Patent number: 9675599
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: June 13, 2017
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity
    Publication number: 20170096412
    Abstract: This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and ?2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
    Type: Application
    Filed: December 15, 2016
    Publication date: April 6, 2017
    Inventors: Adam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric L. STANGELAND, Richard D. WILSON, Rose YEN